N/A N=212 Midlines and Thrombophlebitis
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=217 Central Venous Access Study
Central Line Catheters
Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents
N/A N=152 Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
Phase 3 N=105 Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Upper Extremity Deep Vein Thrombosis · Central Venous Catheter Thrombosis · Cancer
Primary: Primary Feasibility Outcome - Number of Participants Recruited Per Month — 7.5; 2.0 Average enrolment rate/month/site
N/A N=27 Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
Phase 3 N=692 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
N/A N=339 Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
Venous Thrombosis
Primary: Evidence of PICC-related Venous Thrombosis — 102; 95 Participants
N/A N=101 Heparin and the Reduction of Thrombosis (HART) Trial
Thrombosis
Primary: Thrombosis — 8; 6 participants
Phase 2 N=20 t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
Central Venous Catheter Thrombosis · Central Venous Catheter Associated Bloodstream Infection
Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants
N/A N=134 Pediatric Catheter-related Thrombosis Imaging Study
Thrombosis
Primary: Total Number of Participants Who Completed the Study-Related Ultrasound (US) and Magnetic Resonance Imaging (MRI) With and Without Contrast — 133; 113; 113; 110…
Phase 3 N=246 A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Dysfunctional Central Venous Access Catheters
Primary: Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase — 72.0 percentage…
Phase 3 N=1,046 Cancer Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE) · Deep Vein Thrombosis (DVT) · Pulmonary Embolism (PE)
Primary: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event — 67; 71 Participants — p=0.0056
Phase 3 N=100 A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Dysfunctional Central Venous Access Catheters
Primary: Percentage of Patients Who Had Restoration of Central Venous Catheter (CVC) Function Following a Single Administration of Study Drug — 23.4; 60.0 percentage of…
N/A N=101 Observational Study of Complications Related to Use of Peripherally Inserted Central Catheters
Adult Patients With Peripherally Inserted Central Catheters
Primary: Rate of PICC Line Occlusions — 37 percentage of enrolled subjects
N/A N=80 Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters
Hemodialysis
Primary: Blood Flow Rate at First Use After Insertion — 277; 383 mL/min
N/A N=26 Strategies for Anticoagulation During Venovenous ECMO
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
Phase 3 N=16 Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion
Catheter Obstruction · Vascular Access Devices
Primary: Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication — 83.3; 10.0 percentage of participants
Phase 4 N=8 rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Development of CVAD Line Thrombosis — 0 thromboses
Phase 2 N=82 Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
N/A N=100 Femoral Central Venous Access Comparison of 2 Methods
Child
Primary: Installation on the First Try — 18; 42 percentage of participants
N/A N=50 Ultrasound-Guided Peripheral Venous Access Using AccuCath
Intravenous Access
Primary: First Attempt Success Rate — 17; 11 Participants
N/A N=204 AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
Phase 1 N=8 Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
N/A N=1,175 Toronto Thromboprophylaxis Patient Safety Initiative
Venous Thromboembolism
Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients
N/A N=30 Evaluation of the Surfacer System Approach to Central Venous Access
Venous Occlusion
Primary: Number of Participants With Safe Insertion and Patency of Central Venous Access Catheter — 30 participants — p=0.5
N/A N=411 Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
N/A N=149 VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial
Pulmonary Embolism
Primary: Technical Success — 89 participants
N/A N=165 Passive Disinfection Cap Compliance Study
Infection, Hospital
Primary: Disinfecting Barrier Cap Compliance — 98.43 percentage of connector with compliance
N/A N=129 Celect Vena Cava Filter Clinical Trial
Pulmonary Embolism · Venous Thromboembolism
Primary: Major Adverse Event — 0; 1; 2; 0 participants
N/A N=58 Superior Vena Cava and Its Relationship to Central Venous Pressure Measurements in Liver Transplantation
Liver Failure
Primary: Central Venous Pressure (CVP) — 11.7 mmHg